What is New on Thyroid Cancer Biomarkers
Thyroid cancer harbours in about 5% of thyroid nodules. The majority of them are well-differentiated cancers originating from the follicular epithelium, and are subdivided into papillary and follicular carcinomas. Undifferentiated carcinomas and medullary thyroid carcinomas arising from C cells are...
Main Authors: | Rosaria M. Ruggeri, Alfredo Campennì, Sergio Baldari, Francesco Trimarchi, Maria Trovato |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2008-01-01
|
Series: | Biomarker Insights |
Online Access: | https://doi.org/10.4137/BMI.S669 |
Similar Items
-
What is New on Thyroid Cancer Biomarkers
by: Maria Trovato, et al.
Published: (2008-01-01) -
To screen or not to screen for medullary thyroid cancer? This is (yet) the question. An illustrative case.
by: Rosaria Ruggeri, et al.
Published: (2018-12-01) -
Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target
by: Maria Trovato, et al.
Published: (2017-03-01) -
Thyroid dysfunction in patients treated with the immune checkpoint inhibitor nivolumab: different clinical features
by: Giuseppe Giuffrida, et al.
Published: (2017-12-01) -
Coexistence of diffuse large B-cell lymphoma and papillary thyroid carcinoma in a patient affected by Hashimoto's thyroiditis
by: Maria Trovato, et al.